Previous 10 | Next 10 |
A Penny Stocks Watch List To Kick-Start September Are you putting together a list of penny stocks to watch for September? If you are, then you’re not alone, and this article will break down a few stocks under $5 that traders are watching at the start of September. Indeed, all...
Geron Corporation (NASDAQ: GERN) , a late-stage biotech company, saw its shares rise as much as 15.2% on Wednesday, though it closed the day 14.78% higher. The stock, which closed at $2.30 on Tuesday, rose to a high of $2.65 on Wednesday and closed at $2.64, just a little under its ...
- Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib - Study intended to explore potential for disease modification with imetelstat in earlier, frontline myelofibrosis setting - Single-agent imetelstat currently being studied in a sepa...
Geron ( NASDAQ: GERN ) is trading ~6% higher after the company posted narrower-than-expected quarterly loss. The company's Q2 GAAP EPS of -$0.07 beat estimates by $0.02. Total operating expenses for the three months were $28M, compared to $29M, a year ...
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q2 2022 Earnings Call Transcript
Geron Corporation (GERN) Q2 2022 Earnings Conference Call August 11, 2022, 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications Dr. John Scarlett - Chairman and CEO Olivia Bloom - Executive Vice President...
The following slide deck was published by Geron Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Geron Corporation 2022 Q2 - Results - Earnings Call Presentation
Geron press release ( NASDAQ: GERN ): Q2 GAAP EPS of -$0.07 beats by $0.02 . Revenue of $0.07M (-30.0% Y/Y) misses by $0.04M . For FY2022, under generally accepted accounting principles (GAAP), the company continues to expect total operating expenses in the ran...
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024 Conference Call Scheduled for 4:30 p.m. ET ...
Geron ( NASDAQ: GERN ) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close. The consensus EPS Estimate is -$0.09 (flat Y/Y) and the consensus Revenue Estimate is $0.11M (+10.0% Y/Y). Over the last 3 months, EPS estimates have seen ...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...